What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

What question did this study set out to answer?

Evaluate the efficacy and safety of BCMA CAR-T therapy in frontline treatment for transplant-ineligible primary plasma cell leukemia patients.

December 8, 2025BloodOpen Access

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

View Full Paper

Ask AI

Bookmark

Authors

HZHesong Zou SDShuhui Deng LQLugui Qiu

Discussion

Member takes

Overview

Phase 2 trial shows BCMA CAR T-cell therapy improves outcomes in newly diagnosed primary plasma cell leukemia, indicating potential for broader clinical application.

Key Points

Evaluate the efficacy and safety of BCMA CAR-T therapy in frontline treatment for transplant-ineligible primary plasma cell leukemia patients.
Single-arm, phase 2 trial enrolling patients ineligible for ASCT
Patients received lymphodepletion followed by BCMA CAR-T infusion
Primary endpoints were safety and MRD negativity; secondary endpoints included CRR, PFS, OS, and DOR.
Overall response rate was 100% among infused patients
87.5% achieved stringent complete response
All patients reached MRD negativity by next-generation flow cytometry
No relapses or deaths observed at median follow-up of 15.4 months

Cite This Study

Zou et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1e3 https://doi.org/10.1182/blood-2025-257

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)

View Full Paper

Ask AI

Bookmark

Authors

HZHesong Zou SDShuhui Deng LQLugui Qiu

Discussion

Member takes

Overview

Phase 2 trial shows BCMA CAR T-cell therapy improves outcomes in newly diagnosed primary plasma cell leukemia, indicating potential for broader clinical application.

Key Points

Evaluate the efficacy and safety of BCMA CAR-T therapy in frontline treatment for transplant-ineligible primary plasma cell leukemia patients.
Single-arm, phase 2 trial enrolling patients ineligible for ASCT
Patients received lymphodepletion followed by BCMA CAR-T infusion
Primary endpoints were safety and MRD negativity; secondary endpoints included CRR, PFS, OS, and DOR.
Overall response rate was 100% among infused patients
87.5% achieved stringent complete response
All patients reached MRD negativity by next-generation flow cytometry
No relapses or deaths observed at median follow-up of 15.4 months

Cite This Study

Zou et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1e3 https://doi.org/10.1182/blood-2025-257

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark